Miscellaneous musculoskeletal disorders:

Indications for: KEVEYIS

Primary hyperkalemic or hypokalemic periodic paralysis and related variants.

Adult Dosage:

Initially 50mg twice daily. Adjust dose based on response, at weekly intervals (or sooner if adverse reactions occur); max 200mg daily. Evaluate after 2 months.

Children Dosage:

Not established.

KEVEYIS Contraindications:

Concomitant high-dose aspirin. Severe pulmonary disease. Hepatic insufficiency. Sulfonamides.

KEVEYIS Warnings/Precautions:

Discontinue at first sign of skin rash or immune-mediated or idiosyncratic adverse reaction. Adrenocortical insufficiency, hyperchloremic metabolic acidosis, respiratory acidosis: increased risk of hypokalemia. Metabolic acidosis. Monitor serum potassium and bicarbonate at baseline and periodically during treatment; reduce dose or discontinue if hypokalemia or metabolic acidosis develops. Increased risk of falls (esp. elderly, higher doses); consider dose reduction or discontinuation if occurs. Elderly. Pregnancy (Cat.C). Nursing mothers.

KEVEYIS Classification:

Carbonic anhydrase inhibitor.

KEVEYIS Interactions:

Caution with concomitant low-dose aspirin. Increased risk of hypokalemia with loop or thiazide diuretics, laxatives, antifungals, penicillin, and theophylline.

Adverse Reactions:

Paresthesia, cognitive disorder, dysgeusia, confusion, hypoesthesia, lethargy, dizziness, nausea, fatigue, muscle spasms, rash; hypersensitivity reactions.

Drug Elimination:

Half-life: 32-66 hours.

Generic Drug Availability:


How Supplied: